TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer

Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies.

(2017) Y. Pan et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours

(2011) Y Pan et al.   BRITISH JOURNAL OF CANCER

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

(2010) Paula J. Kaplan-Lefko et al.   CANCER BIOLOGY & THERAPY

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

(2010) Andres Forero-Torres et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

(2010) T. Doi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Death Receptor Agonists as a Targeted Therapy for Cancer

(2010) J. Wiezorek et al.   CLINICAL CANCER RESEARCH

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

(2010) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling

(2010) Stephen J. Zoog et al.   CYTOMETRY PART A

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

(2010) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER